Skip to main content

Table 1 Baseline clinico-demographic parameters and health utility scores in GS-US-337-0113 and GS-US-334-0118

From: Health utilities using SF-6D scores in Japanese patients with chronic hepatitis C treated with sofosbuvir-based regimens in clinical trials

  LDV/SOF LDV/SOF + RBV SOF + RBV P All
N 171 170 153   494
Age, years 59.7 ± 9.2 59.2 ± 9.5 56.8 ± 10.1 0.0310 58.6 ± 9.7
Male 69 (40.4%) 73 (42.9%) 70 (45.8%) 0.62 212 (42.9%)
HCV genotype 1 171 (100.0%) 170 (100.0%) 0 (0.0%) <0.0001 341 (69.0%)
HCV genotype 2 0 (0.0%) 0 (0.0%) 153 (100.0%) 153 (31.0%)
Treatment-naïve 83 (48.5%) 83 (48.8%) 90 (58.8%) 0.11 256 (51.8%)
Cirrhosis 41 (24.0%) 35 (20.6%) 17 (11.1%) 0.0097 93 (18.8%)
History of anxiety 8 (4.7%) 4 (2.4%) 3 (2.0%) 0.30 15 (3.0%)
History of depression 3 (1.8%) 7 (4.1%) 5 (3.3%) 0.44 15 (3.0%)
History of insomnia 24 (14.0%) 21 (12.4%) 21 (13.7%) 0.89 66 (13.4%)